Introduction. We developed a Social Observatory in the HealthCare (HC) & Pharma sector to better understand how the focus by Pharma companies on social communication has been implemented, following the new legislation that allows social advertising for over the counter (OTC) drugs. Methods and results. Activity on social networks between 01/06/2018 and 31/05/2019 has been analysed. The social channels monitored were: Facebook, Instagram, LinkedIn, Twitter and YouTube. Activity from 13 companies with HQ in Italy (Abiogen, Alfasigma, Angelini, Chiesi, Doc Generici, Dompé, Italfarmaco, Kedrion, Mediolanum, Menarini, Molteni, Recordati, Zambon) and 16 companies with HQ elsewhere (Abbvie, Amgen, Amway, Bayer, Gilead, GSK - Glaxo SmithKline, J&J/Janssen, Merck Serono, MSD, Nature’s Bounty, Novartis, P&G, Pfizer, Reckitt Benckiser, Roche, Sanofi) was captured and analysed using both quantitative and qualitative techniques. Italy HQ companies seem to use these channels to a lesser extent compared to companies HQs elsewhere. Examples of all the different Brand characters (i.e. Friendly, Playful, Warm, etc), tones (personal, honest, humble, etc) and purposes (engage, entertain, educate, etc) were captured and discussed in detail in the article. Conclusions. Pharma companies have a wide-ranging approach to communicating through social media. These data represent an important baseline to carefully analyse the evolution of social communication of HC&Pharma sector in Italy.

Comunicazione social delle aziende Pharma in Italia: analisi quantitativa e qualitativa dei dati ricavati da un Osservatorio Social / F. Tissoni, G. Venditti, M. Canzano. - In: ABOUTOPEN. - ISSN 2465-2628. - 8:(2021), pp. 35-47. [10.33393/ao.2021.2274]

Comunicazione social delle aziende Pharma in Italia: analisi quantitativa e qualitativa dei dati ricavati da un Osservatorio Social

F. Tissoni
Methodology
;
2021

Abstract

Introduction. We developed a Social Observatory in the HealthCare (HC) & Pharma sector to better understand how the focus by Pharma companies on social communication has been implemented, following the new legislation that allows social advertising for over the counter (OTC) drugs. Methods and results. Activity on social networks between 01/06/2018 and 31/05/2019 has been analysed. The social channels monitored were: Facebook, Instagram, LinkedIn, Twitter and YouTube. Activity from 13 companies with HQ in Italy (Abiogen, Alfasigma, Angelini, Chiesi, Doc Generici, Dompé, Italfarmaco, Kedrion, Mediolanum, Menarini, Molteni, Recordati, Zambon) and 16 companies with HQ elsewhere (Abbvie, Amgen, Amway, Bayer, Gilead, GSK - Glaxo SmithKline, J&J/Janssen, Merck Serono, MSD, Nature’s Bounty, Novartis, P&G, Pfizer, Reckitt Benckiser, Roche, Sanofi) was captured and analysed using both quantitative and qualitative techniques. Italy HQ companies seem to use these channels to a lesser extent compared to companies HQs elsewhere. Examples of all the different Brand characters (i.e. Friendly, Playful, Warm, etc), tones (personal, honest, humble, etc) and purposes (engage, entertain, educate, etc) were captured and discussed in detail in the article. Conclusions. Pharma companies have a wide-ranging approach to communicating through social media. These data represent an important baseline to carefully analyse the evolution of social communication of HC&Pharma sector in Italy.
Big Pharma; Digital communication; HealthCare; Social communication; Social network
Settore SPS/08 - Sociologia dei Processi Culturali e Comunicativi
https://journals.aboutscience.eu/index.php/aboutopen/article/view/2274/2370
Article (author)
File in questo prodotto:
File Dimensione Formato  
articolo aboutopen.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.75 MB
Formato Adobe PDF
1.75 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/851586
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact